A Brucella melitensis H38ΔwbkF rough mutant protects against Brucella ovis in rams

Pilar M Muñoz1,2, Raquel Conde-Álvarez3, Sara Andrés-Barranco4,5

  • 1Departamento de Ciencia Animal, Centro de Investigación y Tecnología Agroalimentaria de Aragón (CITA), Zaragoza, Spain. pmmunnoz@cita-aragon.es.

Veterinary Research
|March 3, 2022
PubMed

Insights

Developing a new vaccine for Brucella ovis is crucial for sheep farming. The H38ΔwbkF vaccine candidate shows promise, offering protection against B. ovis without interfering with Brucella melitensis diagnosis.

Area of Science:

  • Veterinary Microbiology
  • Immunology
  • Animal Health

Background:

  • Brucella melitensis and Brucella ovis cause significant economic losses in sheep.
  • Current B. melitensis Rev 1 vaccine interferes with serological diagnosis of B. melitensis.
  • Need for a B. ovis-specific vaccine that does not cross-react with B. melitensis.

Purpose of the Study:

  • To develop and evaluate novel live vaccine candidates for Brucella ovis.
  • To identify a vaccine that elicits protection against B. ovis without cross-reactivity in B. melitensis diagnostic tests.

Main Methods:

  • Investigated three Brucella live vaccine candidates lacking N-formyl-perosamine O-polysaccharide.
  • Assessed attenuation and protection against B. ovis in mice and rams.
  • Evaluated antibody responses using ELISA, immunoprecipitation, Rose Bengal, and complement fixation tests.

Main Results:

  • H38ΔwbkF demonstrated protection against B. ovis comparable to Rev 1 in rams.
  • Bov::CAΔwadB and Rev1::wbdRΔwbkC provided poor or no protection.
  • H38ΔwbkF induced B. ovis-specific antibodies but did not interfere with routine B. melitensis serological tests.

Conclusions:

  • H38ΔwbkF is a promising candidate for B. ovis immunoprophylaxis in B. melitensis-free regions.
  • This vaccine avoids serological interference, facilitating simultaneous eradication and surveillance programs.